Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Other financing activities (2021 - 2022)

Prime Medicine filings provide 2 years of Other financing activities readings, the most recent being $1.4 million for Q4 2022.

  • On a quarterly basis, Other financing activities rose 28.91% to $1.4 million in Q4 2022 year-over-year; TTM through Sep 2023 was $1.4 million, a 62.45% decrease, with the full-year FY2022 number at $4.0 million, up 272.19% from a year prior.
  • Other financing activities hit $1.4 million in Q4 2022 for Prime Medicine, up from $746000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.4 million in Q4 2022 to a low of $624000.0 in Q2 2022.